From the Guidelines
No, it is not appropriate to add Reyvow (lasmiditan) to a diabetes management regimen. Reyvow is specifically approved for the acute treatment of migraine headaches with or without aura in adults, not for diabetes management. Diabetes treatment typically includes medications like metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or insulin, depending on the type of diabetes and individual patient factors 1. Reyvow works by acting as a selective serotonin 5-HT1F receptor agonist in the central nervous system to treat migraines, which has no therapeutic benefit for controlling blood glucose levels or addressing any diabetes-related complications. Adding Reyvow to a diabetes regimen would expose the patient to unnecessary side effects such as dizziness, fatigue, and sedation without providing any glycemic control benefits. If a patient with diabetes also suffers from migraines, Reyvow could be prescribed specifically for migraine management as a separate treatment, but it should never be considered part of the diabetes management strategy itself. The American Diabetes Association recommends a patient-centered approach to diabetes management, considering factors such as efficacy, hypoglycemia risk, effect on weight, side effects, and cost when choosing glucose-lowering agents 1. Reyvow does not meet these criteria for diabetes management, and its use in this context is not supported by current evidence. Therefore, Reyvow should not be added to a diabetes management regimen.
From the Research
Addition of Reyvow (Lasmiditan) to Diabetes Management Regimen
There is no direct evidence to suggest the addition of Reyvow (lasmiditan) to a diabetes management regimen. The provided studies focus on the management of type 2 diabetes using various therapies such as insulin, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-dependent glucose cotransporter-2 inhibitors (SGLT2is) 2, 3, 4, 5, 6.
Current Therapies for Type 2 Diabetes
- GLP-1RAs have been shown to be effective in lowering HbA1c levels with little hypoglycemia risk and also ameliorating body weight, blood pressure, and lipid levels 4.
- SGLT2is have demonstrated clinically significant benefits on glycated hemoglobin, weight, blood pressure, and cardiorenal outcomes 5, 6.
- The combination of GLP-1RAs and SGLT2is is an emerging option for managing adults with type 2 diabetes, offering potential additive effects on A1C reduction, weight reduction, and blood pressure reduction 5, 6.
Conclusion on Reyvow (Lasmiditan)
Since there are no research papers to assist in answering this question, it is not possible to provide evidence-based information on the addition of Reyvow (lasmiditan) to a diabetes management regimen.